Global Nanobiosensors in Healthcare Market: Information by type (Optical Nanobiosensor, Electrochemical Nanobiosensor, Acoustic Nanobiosensor and others), Application (Diabetes, Immunoassay, Cancer, Pathogenic Bacteria and others), End User (Hospitals and Clinics, Point of Care, Diagnostic Centers and others) - Global Forecast till 2024

Market Scenario

The Global Nanobiosensors in Healthcare Market is expected to register a CAGR of 9.84% from 2019 to 2024.

Nanotechnology in the biosensor is known as nanobiosensor; biosensors are analytical devices used for detection of chemical and biological substances in the human body. Nanobiosensors are the sensors that are made up of nanomaterials and have dimensions between 1 to 100 nanometers. Nanobiosensors are becoming popular in developed countries. The rising prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and raising awareness about advance nanobiosensors are expected to drive the growth of the market. According to the International Diabetes Federation (IDF), it is estimated that the number of diabetic patients in the Middle East and North Africa (MENA) region will grow by 96% from the year 2013 to 2035, i.e., from 34.6 million to 67.9 million. Moreover, rising R&D spending and collaborative strategies adopted by the top players, such as new product launches and collaborations for product development are contributing to the growth of the market.

The rising cost of nanobiosensors and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.

Segmentation

The global nanobiosensors in the healthcare market has been segmented on the basis of type, application, end user, and region.

On the basis of type, the market has been classified as optical nanobiosensors, electrochemical nanobiosensors, acoustic nanobiosensors, and others. Based on the application, the market has been segmented into diabetes, immunoassay, cancer, pathogenic bacteria, and others. The market, by end user, has been classified as hospitals and clinics, diagnostic centers, point of care, and others. The electrochemical nanobiosensors segment is expected to hold the largest market share of the nanobiosensors in healthcare market owing to its high sensitivity and real-time detection features. However, based on end user point of care testing segment holds the largest market share due to low complex infrastructure and training.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nanobiosensors in the healthcare market in the Americas has further been segmented into North America and South America, with the North America market further divided into the US and Canada.

The European nanobiosensors in the healthcare market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The nanobiosensors in healthcare market in Asia-Pacific has been segmented into Japan, China,
India, South Korea, Australia, and the rest of Asia-Pacific. The nanobiosensors in healthcare market in the Middle East & Africa has been segmented into the Middle East and Africa.

**Key Players**


**Regional Market Summary**

**Global Nanobiosensors in Healthcare Market Share, by Region, 2018 (%)**

Source: MRFR Analysis

The Americas are likely to dominate the global nanobiosensors in healthcare market owing to the rising prevalence of chronic disorders, initiative by government and regulatory authorities, and demands for advanced technology. According to the report published by the US Department of Health & Human Services, in 2017, around 11.5% of the adult population in the US are diagnosed with heart disease, i.e., 28.2 million.

The European market is expected to be the second largest nanobiosensors in healthcare market. The market growth in this region can be attributed to the government focus to control chronic disease, well-established healthcare infrastructure, and the rising population suffering from cardiovascular disorders. Moreover, government funding and support to the healthcare sector are also expected to boost the growth of the nanobiosensors in healthcare market during the forecast period. According to the European Heart Network, cardiovascular disorders are responsible for 3.9 million deaths in the European Union, which are 45% of the total deaths.

Asia-Pacific is expected to be the fastest-growing nanobiosensors in healthcare market during the forecast period owing to rising diabetes, increasing disposable income, and government initiatives for the development of the healthcare sector. According to the International Diabetes Federation, in 2017, more than 84 million people in South-East Asia were affected by diabetes, and this number is expected to reach 156 million by 2045. Moreover, the government of these countries is open to adopting new technology and the best treatment option from a developed country. According to the International Agency for Research on Cancer, in 2018, India has a prevalence of 173.5 cancer patients per 100,000 population. Moreover, in China, the prevalence rate of cancer was 377.6 patients per 100,000 population in 2018

The market in the Middle East & Africa is expected to hold the smallest share of the global nanobiosensors market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

**Global Nanobiosensors in Healthcare Market, by Type**

- Optical Nanobiosensors
- Electrochemical Nanobiosensors
- Acoustic Nanobiosensors
- Others
Global Nanobiosensors in Healthcare Market, by Application

- Diabetes
- Immunoassay
- Cancer
- Pathogenic Bacteria
- Others

Global Nanobiosensors in Healthcare Market, by End User

- Hospitals & Clinics
- Diagnostic Centre
- Point of Care Testing
- Others

Global Nanobiosensors in Healthcare Market, by Region

- **Americas**
  - North America
    - US
    - Canada
  - Latin America

- **Europe**
  - Western Europe
    - Germany
    - France
    - Italy
    - Spain
    - UK
    - Rest of Western Europe
  - Eastern Europe

- **Asia-Pacific**
  - Japan
  - China
  - India
  - Australia
  - South Korea
  - Rest of Asia-Pacific

- **Middle East & Africa**
  - Middle East
  - Africa

**Intended Audience**

- Nano Biosensor manufacturers
- Nano Biosensor distributors and suppliers
- Healthcare providers
- Research institutes and academic centers
- Government associations
- Market research and consulting

**Contents:**

Table of Contents:

Chapter 1 Report Prologue

Chapter 2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Detection Technique Trends & Assessment

Chapter 5 Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6 Global Nano Biosensors in Healthcare Market, by Type
6.1 Introduction
6.2 Optical Nanobiosensors
Market Estimates & Forecast, by Region, 2019–2024
6.3 Electrochemical Nanobiosensors
Market Estimates & Forecast, by Region, 2019–2024
6.4 Acoustic Nanobiosensors
Market Estimates & Forecast, by Region, 2019–2024
6.5 Others

Chapter 7 Global Nano Biosensors in Healthcare Market, by Application
7.1 Introduction
7.2 Diabetes
Market Estimates & Forecast, by Region, 2019–2024
7.3 Immunoassay
Market Estimates & Forecast, by Region, 2019–2024
7.4 Cancer
Market Estimates & Forecast, by Region, 2019–2024
7.5 Pathogenic Bacteria
Chapter 8 Global Nano Biosensors in Healthcare Market, by End User

8.1 Introduction
8.2 Hospitals & Clinics
8.3 Diagnostic Centre
8.4 Point of Care Testing
8.5 Others

Chapter 9 Global Nano Biosensors in Healthcare Market, by Region

9.1 Introduction
9.2 Americas
  9.2.1 North America
    9.2.1.1 US
    9.2.1.2 Canada
  9.2.2 Latin America
9.3 Europe
  9.3.1 Western Europe
    9.3.1.1 Germany
    9.3.1.2 France
    9.3.1.3 Italy
    9.3.1.4 Spain
    9.3.1.5 UK
    9.3.1.6 Rest of Western Europe
  9.3.2 Eastern Europe
9.4 Asia-Pacific
  9.4.1 Japan
  9.4.2 China
  9.4.3 India
  9.4.4 Australia
  9.4.5 South Korea
  9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
  9.5.1 Middle East
  9.5.2 Africa

Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Developments & Strategies

Chapter 11 Company Profiles

11.1 Abbott Point of Care, Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financial Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.1.6 Key Strategies

11.2 F. Hoffman-La Roche Ltd.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategies

11.3 Medtronic Inc.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategies

11.4 Nano-Proprietary, Inc.
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategies

11.5 Lifescan, Inc.
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial Overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategies

11.6 Illuminex Corporation
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategies

11.7 Lifesensors, Inc.
11.7.1 Company Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategies
11.8 ACON Laboratories, Inc.
11.8.1 Company Overview
11.8.2 Product Overview
11.8.3 Financial Overview
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.8.6 Key Strategies
11.9 Pharmaco-Kinesis Corporation
11.9.1 Company Overview
11.9.2 Product Overview
11.9.3 Financial Overview
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.9.6 Key Strategies
11.10 Bayer Healthcare AG
11.10.1 Company Overview
11.10.2 Product Overview
11.10.3 Financial Overview
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.10.6 Key Strategies
11.11 Bio-Rad Laboratories, Inc.
11.11.1 Company Overview
11.11.2 Product Overview
11.11.3 Financial Overview
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.11.6 Key Strategies
11.12 Biosensors International Pte. Ltd.
11.12.1 Company Overview
11.12.2 Product Overview
11.12.3 Financial Overview
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.12.6 Key Strategies
11.13 Sysmex Corporation
11.13.1 Company Overview
11.13.2 Product Overview
11.13.3 Financial Overview
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.13.6 Key Strategies
11.14 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings
12.1.1 From CEO’s Viewpoint
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Predictions for the Nano Biosensors in Healthcare Industry

Chapter 13 Appendix

LIST OF TABLES
Table 1 Global Nano Biosensors in Healthcare Market Synopsis, 2019–2024
Table 2 Global Nano Biosensors in Healthcare Market Estimates and Forecast, 2019–2024 (USD Million)
Table 3 Global Nano Biosensors in Healthcare Market, by Region, 2019–2024 (USD Million)
Table 4 Global Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 5 Global Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 6 North America: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 7 North America: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 8 US: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 9 US: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 10 Canada: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 11 Canada: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 12 Latin America: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 13 Latin America: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 14 Europe: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 15 Europe: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 16 Western Europe: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 17 Western Europe: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 18 Eastern Europe: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 19 Eastern Europe: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 20 Asia-Pacific: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 21 Asia-Pacific: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)
Table 22 Middle East & Africa: Nano Biosensors in Healthcare Market, by Type, 2019–2024 (USD Million)
Table 23 Middle East & Africa: Nano Biosensors in Healthcare Market, by Application, 2019–2024 (USD Million)

LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Nano Biosensors in Healthcare Market
Figure 3 Segmentation Market Dynamics for Global Nano Biosensors in Healthcare Market
Figure 4 Global Nano Biosensors in Healthcare Market Share, by Type, 2018
Figure 5 Global Nano Biosensors in Healthcare Market Share, by Region, 2018
Figure 6 Global Nano Biosensors in Healthcare Market Share, by Type, 2018
Figure 7 North America: Nano Biosensors in Healthcare Market Share, by Country, 2018
Figure 8 Europe: Nano Biosensors in Healthcare Market Share, by Country, 2018
Figure 9 Asia-Pacific: Nano Biosensors in Healthcare Market Share, by Country, 2018
Figure 10 Middle East & Africa: Nano Biosensors in Healthcare Market Share, by Country, 2018
Figure 11 Global Nano Biosensors in Healthcare Market: Company Share Analysis, 2018 (%)
Figure 12 Abbott Point of Care, Inc.: Key Financials
Figure 13 Abbott Point of Care, Inc.: Segmental Revenue
Figure 14 Abbott Point of Care, Inc.: Geographical Revenue
Figure 15 F. Hoffman-LA Roche Ltd.: Key Financials
Figure 16 F. Hoffman-LA Roche Ltd.: Segmental Revenue
Figure 17 F. Hoffman-LA Roche Ltd.: Geographical Revenue